BrightGene Bio-Medical halts A-share plan, eyes H-share listing

BrightGene Bio-Medical Technology (SSE:688166) announced on October 16, 2025, the termination of its 2024 non-public issuance of A-shares and the withdrawal of related application documents from the Shanghai Stock Exchange. The decision, approved by the board of directors on October 15, 2025, followed comprehensive consideration of prevailing capital market conditions, the company’s development plans, and macro and micro-economic factors, aiming to protect shareholder interests.

The A-share issuance had undergone several revisions since its initial approval on May 6, 2024, with subsequent amendments on May 8, 2025, and July 18, 2025. The application was accepted by the Shanghai Stock Exchange on August 8, 2025. The company stated that the termination would not significantly impact its normal operations or stable development.

Concurrently, BrightGene Bio-Medical is proceeding with plans for an H-share listing on the Main Board of the Hong Kong Stock Exchange, as evidenced by the board's approval of revised internal governance documents. These revisions include updated policies on related-party transactions, information disclosure, board diversity, and employee diversity, effective upon the H-share listing and regulatory filings.